To date, PDE4 and possibly PDE3 have been shown to be pharmacologically relevant targets in COPD (see references above and refs. [1,9] for reviews) and fibrotic lung disease (see references above). The gene discussed is PDE4A; the disease is chronic obstructive pulmonary disease.